{"id":"https://genegraph.clinicalgenome.org/r/ff7b6e35-065f-44ec-babf-f5a0d7e47bb1v1.0","type":"EvidenceStrengthAssertion","dc:description":"*IL10*, also known as *CSIF*, was first reported in relation to autosomal recessive early-onset inflammatory bowel disease (IBD) in 2010 (Glocker EO, et al., PMID: 20934598). Individuals reported to date with IL10-associated early-onset IBD have presented with IBD with an onset between 1 month and 5 years of age without additional characteristic features.\n\nThree variants (missense) that have been reported in four unrelated probands in three publications (PMIDs: 20934598, 22549091, 29248579) are included in this curation. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by animal models, expression studies, and in vitro functional assays (PMIDs: 8770874, 9312047, 15534372, 1578140, 17137799, 1827484, 22549091, 23158016). IL10 is a well-established anti-inflammatory cytokine (PMID: 1827484, 1578140, 33691712). In vitro experiments have demonstrated that mutant IL10 carrying patient-associated variants displayed impaired suppression of TNFa production by stimulated PBMCs (PMID: 22549091, 23158016). Multiple mouse models of IL10 deficiency, including *IL10*-knockout and CD4-specific *IL10* knockout mice, recapitulate the spontaneous intestinal inflammation in human disease (PMID: 8770874, 15534372). Notably, both IL10Ra and IL10RB, the subunits of the receptor with which IL10 directly interacts (PMID: 9312047), are also associated with early-onset IBD (PMID: 39795980).\n\nIn summary, there is moderate evidence to support this gene-disease relationship. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/ff7b6e35-065f-44ec-babf-f5a0d7e47bb1","GCISnapshot":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10145","date":"2025-02-18T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10145","date":"2025-03-04T17:06:48.219Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c0b1acc5-3c8e-4435-878f-30da455dd3bb","type":"EvidenceLine","dc:description":"CD4-specific deletion of IL10 resulted in phenotype recapitulating human disease. Supporting the importance of IL10 derived from CD4 T cells in preventing intestinal inflammation","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/48c98ada-8da9-4b1d-9bd9-2e8d3a1b9d9f","type":"Finding","dc:description":"Deletion of IL-10 from CD4 expressing cells (T cells) resuted in spontaneous IBD","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15534372","rdfs:label":"CD4-specific IL10-/- results in intestinal inflammation","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/573271bb-ae11-42bc-8120-1c50a768c1c6","type":"EvidenceLine","dc:description":"Targeted deletion of IL10 in mice results in phenotype consistent with humans phenotype with high penetrance (complete penetrance on some mouse backgrounds by 3 moths). ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05440c76-5895-41c3-affd-eff9b98d2878","type":"Finding","dc:description":"IL10-/- mice develop spontaneous IBD under SPF conditions (69% by 3 wks and 100% by 3 months of age)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/8770874","rdfs:label":"IL10-/- mice develop spontaneous enterocolitis","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1ea37ddb-74d5-4e72-8d33-08989f1e49dc","type":"EvidenceLine","dc:description":"Inhibition of inflammatory cytokine IFNg by IL10 consistent with increased inflammation observed in patients with IL10 variant-associated IBD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/84349b25-4c49-4d0e-8295-0301e8f4334a","type":"Finding","dc:description":"Increased inflammation associated with IBD-IL10 known anti-inflammatory cytokine. IFN-Î³-producing CD4+ T cells (Th1 type) shown to play a causal role in the development of enterocolitis affecting these mutants. PMID: 8691138","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1827484","rdfs:label":"IL10 inhibits inflammatory cytokine production by T cells","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/0b2082dd-a309-440f-bdea-91b605cf61e7","type":"EvidenceLine","dc:description":"Anti-inflammatory properties by IL10 indicated here by it's ability to inhibit T cell proliferation consistent with increased inflammation in patients with IL10 variant-associated IBD. CD4 T cells previously implicated to have a significant role in disease (PMID: 8691138). ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d86cfa4-b6cc-4780-9fb6-3649aeb2e944","type":"Finding","dc:description":"Increased inflammation in intestine in IBD with CD4 T cells implicated to have a significant role in disease (PMID: 8691138). IL10 known to have anti-inflammatory properties.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1578140","rdfs:label":"IL10 inhibits T cell proliferation","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9b7738c3-aea9-48e0-9871-dfb2f1eade9d","type":"EvidenceLine","dc:description":"IL10 directly interacts with the IL10R. Defects in both components of the IL10R , IL10Ra and IL10RB, are associated with early onset IBD in humans (a similar phenotype to individuals with IL10 defects).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86cfe955-b1c2-4587-b18e-16c716089bf7","type":"Finding","dc:description":"IL10 binds to a receptor consisting of IL10Ra and IL10RB. This paper demonstrates a direct interaction between IL10 and IL10R. Both IL10Ra and IL10RB are associated with early onset IBD.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9312047","rdfs:label":"IL10 interacts with IL10Ra/IL10RB","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/c770b963-36c4-429c-99a0-147f74b19642","type":"EvidenceLine","dc:description":"Demonstrates expression of IL10 in immune cells, notably T cells but also macrophages and DCs. Significant expression found in IELs, Peyer's patches. and mesenteric lymph nodes, consistent with intestinal inflammation in IL10 deficient patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6f28d32c-a0cc-455b-89e2-5047dbbe628e","type":"Finding","dc:description":"IL-10 expression was linked to a GFP reporter in a mouse line (i.e. \"tiger\" mice). IL10 was found to be expressed in BM macrophages (unstimulated and higher expression with stimulation), stimulated BM DCs in vitro. In vivo, mice were stimulated with staphylococcal enterotoxin A (SEA) and IL10 expression was significantly detected in TCRAB IELs and Peyer's patches, as well as in the spleen and mesenteric lymph nodes to lower levels. After anti-CD3 injection, IL10 was significantly expressed in CD8 aB, CD8 aa, TCRgd, and TCRaB cells. IL10 was highly expressed in Foxp3+ cells after anti-CD3 treatment.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17137799","rdfs:label":"IL10-GFP reporter in mice","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/4b07cbe7-442e-421f-8fc9-7344027dd7dc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1600a87b-955b-4fec-abdc-1ecfb4d6d71e_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03f86de4-da6b-4d70-b67a-0038f715b3b6","type":"EvidenceLine","dc:description":"Variant is absent from gnomAD v2 and v4, REVEL score of 0.664 (inconclusive), functional data supports mutant IL10 has defect in anti-inflammatory function (PMID: 23158016)","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03f86de4-da6b-4d70-b67a-0038f715b3b6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant IL-10 as expressed in patients 8 and 9 did not inhibit TNFa release as measured by ELISA in LPS-challenged PBMCs from healthy donors (23158016).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/03f86de4-da6b-4d70-b67a-0038f715b3b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20934598","allele":{"id":"https://genegraph.clinicalgenome.org/r/2cc9ccbe-d46e-4bfa-b069-d7f11f32d8c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000572.3(IL10):c.337G>A (p.Gly113Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA344482004"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/1600a87b-955b-4fec-abdc-1ecfb4d6d71e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20934598","rdfs:label":"Patient 2","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2cc9ccbe-d46e-4bfa-b069-d7f11f32d8c1"},"detectionMethod":"Sanger sequencing of IL10","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"ulceration of ileum, active colitis","phenotypes":["obo:HP_0003261","obo:HP_0002583","obo:HP_0002573","obo:HP_0003496","obo:HP_0002014"],"previousTesting":true,"previousTestingDescription":"Sanger sequencing of IL10R, which was negative","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/03f86de4-da6b-4d70-b67a-0038f715b3b6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/53a2eda7-5f8b-4cb3-ba7b-eaabbab9c734_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/644c6932-f6b9-4977-bf34-94ce10860ef5","type":"EvidenceLine","dc:description":"REVEL Score: 0.374, not in ClinVar, absent from v2, no functional data","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/644c6932-f6b9-4977-bf34-94ce10860ef5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29248579","allele":{"id":"https://genegraph.clinicalgenome.org/r/6f94072e-320e-41ef-a46b-153db2375ffc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000572.3(IL10):c.314T>A (p.Ile105Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA36549307"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/53a2eda7-5f8b-4cb3-ba7b-eaabbab9c734","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29248579","rdfs:label":"P21","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/6f94072e-320e-41ef-a46b-153db2375ffc"},"detectionMethod":" XIAP, IL10, IL10RA, IL10RB sequenced","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"VEO-IBD, Crohn's disease-like","phenotypes":"obo:HP_0002037","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/644c6932-f6b9-4977-bf34-94ce10860ef5_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/61752a8a-96df-4d2e-92d9-680c63d5f843_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bce357f-54b5-4872-bca6-f66262cfec36","type":"EvidenceLine","dc:description":"Variant is absent from gnomAD v2 and v4, REVEL score of 0.664 (inconclusive), functional data supports mutant IL10 has defect in anti-inflammatory function (PMID: 23158016).","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1bce357f-54b5-4872-bca6-f66262cfec36_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant IL-10 as expressed in patients 8 and 9 did not inhibit TNFa release as measured by ELISA in LPS-challenged PBMCs from healthy donors (described in PMID 23158016). ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1bce357f-54b5-4872-bca6-f66262cfec36_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20934598","allele":{"id":"https://genegraph.clinicalgenome.org/r/2cc9ccbe-d46e-4bfa-b069-d7f11f32d8c1"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/61752a8a-96df-4d2e-92d9-680c63d5f843","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20934598","rdfs:label":"Patient 1","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"allele":{"id":"https://genegraph.clinicalgenome.org/r/2cc9ccbe-d46e-4bfa-b069-d7f11f32d8c1"},"detectionMethod":"Sequencing of IL10 gene","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"perianal and rectovaginal fistulae, ileal ulceration; High-output\nstoma after BMT: RSV infection, CMV and EBV infection/reactivation; Colitis resolved after HSCT at 3 y 11mo. ","phenotypes":["obo:HP_0002037","obo:HP_0033222","obo:HP_0000365","obo:HP_0002583"],"previousTesting":true,"previousTestingDescription":"Sequencing of IL10R genes, which was negative","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1bce357f-54b5-4872-bca6-f66262cfec36_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/218d1592-b164-47fb-87fb-0e5185d8fd75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/beb6218e-84f8-45ab-90fb-391c58b2ee08","type":"EvidenceLine","dc:description":"Variant is absent from gnomad v2, REVEL Score: 0.803, in vitro functional studies suggest defective anti-inflammatory affect.","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/beb6218e-84f8-45ab-90fb-391c58b2ee08_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"WT and mutant IL10 expressed by lentiviral in 293T cells. Secreted IL10 was quantified and then the ability to suppress TNFa secretion in healthy LPS-stimulated patient cells assessed. It was found the mutant IL10 did not suppress TNFa secretion, while WT did.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/beb6218e-84f8-45ab-90fb-391c58b2ee08_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22549091","allele":{"id":"https://genegraph.clinicalgenome.org/r/db2aec97-e89e-46bc-9d93-a1bfc86036be","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000572.3(IL10):c.458G>A (p.Gly153Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA344481710"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/218d1592-b164-47fb-87fb-0e5185d8fd75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22549091","rdfs:label":"Patient 15","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":58,"allele":{"id":"https://genegraph.clinicalgenome.org/r/db2aec97-e89e-46bc-9d93-a1bfc86036be"},"detectionMethod":"sequenced the genes encoding for IL-10R1,IL-10R2, and IL-10","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0010447","obo:HP_0005224","obo:HP_0002037"],"previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/beb6218e-84f8-45ab-90fb-391c58b2ee08_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.2}],"evidenceStrength":"Moderate","sequence":10043,"specifiedBy":"GeneValidityCriteria11","strengthScore":9.2,"subject":{"id":"https://genegraph.clinicalgenome.org/r/FJk7ns1LLQo","type":"GeneValidityProposition","disease":"obo:MONDO_0016542","gene":"hgnc:5962","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_4b07cbe7-442e-421f-8fc9-7344027dd7dc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}